GEN Exclusives

More »

GEN News Highlights

More »
Jan 25, 2008

TransTech Pharma Acquires Three Programs Related to Metabolic Disorders from Novo Nordisk

  • TransTech gained all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders. This portfolio comprises three distinct therapeutic approaches: H3 receptor antagonists, PPAR-delta agonists, and 11ßHSD1 inhibitors.

    In January 2007, Novo Nordisk decided to divest all its small molecule projects and concentrate on its protein-based pharmaceutical business.

    With this acquisition, TransTech is engaged in 11 clinical and preclinical programs within diabetes and obesity. The other candidates in the company’s portfolio include novel, orally administered compounds targeting PTP1b inhibitors, AgRP inhibitors, GLP1R agonists, AMPK activators, and glucokinase activators.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?